Literature DB >> 8926649

Clinical characteristics of hepatitis C virus-associated retinopathy.

T Abe1, A Nakajima, N Satoh, T Koizumi, S Sakuragi, T Ono, M Komatsu, O Masamune.   

Abstract

The morbidity rate for retinopathy of unknown origin was significantly higher (P < 0.001) in the chronic hepatitis C group, 27 (31.8%) of 85 cases, than in the control group, 6 (6.0%) of 100 cases. Among hepatitis C virus (HCV)-associated retinopathy patients, 6 cases (22.2%) were aware of ocular subjective symptoms, retinopathy recurred in 8 (29.6%) cases, binocular retinopathy occurred in 14 (51.9%) cases, and retinopathy related to liver dysfunction, in 13 (81.3%) of 16 tested cases. HCV-associated retinopathy involved hemorrhage at the posterior pole retina in 21 (77.8%), cotton-wool patches in 9 (33.3%), and hemorrhage at the peripheral retina in 7 (25.9%) cases. Sequelae occurred in only one case. Retinopathy worsened or recurred in all 7 cases treated with interferon. The risk factors for HCV-associated retinopathy were mild thrombocytopenia (P < 0.001), long-term hepatitis illness (P < 0.005), advanced age (P < 0.02), concurrence with liver cirrhosis (P < 0.02), history of systemic hypertension (P < 0.05), and female gender (P < 0.05).

Entities:  

Mesh:

Year:  1995        PMID: 8926649

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  12 in total

1.  Relationship between retinopathy and cirrhosis.

Authors:  Colakoglu Onder; Taskiran Bengur; Dayi Selcuk; Sozmen Bulent; Unsal Belkis; Maden Ahmet; Pasa Eser; Aslan S Leyla
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

Review 2.  Interferon associated retinopathy.

Authors:  S Hayasaka; Y Nagaki; M Matsumoto; S Sato
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

3.  Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.

Authors:  K Jain; W C Lam; S Waheeb; Q Thai; J Heathcote
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

4.  Decreased tear lactoferrin concentration in patients with chronic hepatitis C.

Authors:  T Abe; A Nakajima; M Matsunaga; S Sakuragi; M Komatsu
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

5.  Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon.

Authors:  Michael R Narkewicz; Philip Rosenthal; Kathleen B Schwarz; Arlene Drack; Todd Margolis; Michael X Repka
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-08       Impact factor: 2.839

Review 6.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.

Authors:  Damien Sene; Valerie Touitou; Bahram Bodaghi; David Saadoun; Gabriel Perlemuter; Nathalie Cassoux; Jean-Charles Piette; Phuc-Le Hoang; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

8.  Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin.

Authors:  Nilesh Mehta; Uma K Murthy; Vivek Kaul; Samuel Alpert; Gerald Abruzzese; Charles Teitelbaum
Journal:  Dig Dis Sci       Date:  2009-02-26       Impact factor: 3.199

9.  Increased Risk of Age-Related Macular Degeneration with Chronic Hepatitis C Virus Infection: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan.

Authors:  Chih-Ching Yeh; Meei-Maan Wu; Chia-Min Wu; Fung-Chang Sung; Chih-Hsin Muo; Arlene Te; Fu-Hsiung Su
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

10.  Alcoholic liver disease and bilateral multifocal central serous retinopathy: a case report.

Authors:  Despoina Gkotsi; Manish Gupta; Gerassimos Lascaratos; Andreas Syrogiannis; Baljean Dhillon
Journal:  J Med Case Rep       Date:  2013-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.